Home »

ONL Therapeutics Closes Series A Financing to Support Development of Novel Retinal Cell Protection Platform for Treatment of Ocular Diseases

Posted by Picture Gallery, Venture Capital Wednesday, May 17th, 2017

Proceeds to Support Final Development of ONL1204 in Preparation for Retinal Detachment Clinical Trials

Vista Partners Updates Coverage on Ohr Pharmaceutical, Inc.; Target Price $3.50

Posted by Investment Services & Trading, Picture Gallery Wednesday, October 17th, 2012

SAN FRANCISCO, CA — (Marketwire) — 10/17/12 — announced today that it has updated coverage on (OTCBB: OHRP) ("The Company" or "OHR") with a twelve month target price of $3.50. Ross Silver, Principal Analyst at Vista Partners, stated, "OHR is developing two drugs: Squalamine Eye Drops, in a Phase 2 trial, for the treatment of the wet form of age-related macular degeneration (Wet-AMD) & OHR/AVR 118, in a Phase 2 trial, for the treatment of Cancer Cachexia. Therap

Analytics

© 2020 88Finance. All Rights Reserved. Log in - Copyright by LayerMedia


Blogverzeichnis - Blog Verzeichnis bloggerei.de Blog Top Liste - by TopBlogs.de